Trial reportThoracic cancer2026
Perioperative Normobaric Hyperoxia Combined With Pulmonary Rehabilitation Intervention for Enhanced Short-Term Recovery in Lung Cancer Surgery.
Trial report in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundOptimizing perioperative management strategies to promote the rapid recovery remains a focus and challenge research. Normobaric hyperoxia enhances antioxidant defenses and promotes tissue repair, improving functional outcomes in stroke patients. This study aimed to investigate the influence of perioperative normobaric hyperoxia combined with pulmonary rehabilitation on video-assisted thoracoscopic surgery-treated lung cancer patients.
methodsThis trial enrolled 100 patients with pulmonary nodules scheduled for video-assisted thoracoscopic surgery (VATS). Eligible patients were randomized in a 1:1 ratio into two groups. The primary outcomes were postoperative length of stay (LOS) and total hospitalization costs. Secondary outcomes included incidence of postoperative pulmonary complications (PPCs), postoperative inflammatory indicators, activities of daily living (ADL), perioperative outcomes, and readmission rates within 30 days and 6 months after discharge.
resultsEighty-four patients completed the study. The intervention group experienced a significantly shorter postoperative LOS (2 days, IQR 1.8 to 3) and lower total hospitalization cost (41 185 RMB, IQR 35094 to 47 028). The intervention group reported better scores of ADL on postoperative (45 points, IQR 33.8 to 55) and discharge (95 points, IQR 90 to 100). But there were no differences in the incidence of PPCs, C-reactive protein, procalcitonin, perioperative outcomes, and readmission rates within 30 days and 6 months after discharge.
conclusionsNormobaric hyperoxia combined with perioperative pulmonary rehabilitation may reduce postoperative LOS and decreased costs for VATS-treated lung cancer patients. This approach expected to optimize outcomes and improve rehabilitation for early-stage lung cancer patients.
trial registrationThe clinical trial was registered on January 17, 2018, with the registration number ChiCTR1800014512.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.